Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …

Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in
incidence and have a poor prognosis. Most patients present with advanced disease, for …

Biliary tract cancer (BTC), comprising< 1% of all human cancers and∼ 10%–15% of all
primary liver cancers, presents mostly in the seventh decade with a small male …

Gallbladder cancer (GBC) is an uncommon disease in the majority of the world despite
being the most common and aggressive malignancy of the biliary tree. Early diagnosis is …

Abstract An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus
meeting of expert panellists was convened on 15 January 2014 to review current evidence …

Cholangiocarcinoma (CCA) encompasses a group of malignancies that can arise at any
point in the biliary tree. Although considered a rare cancer, the incidence of CCA is …

Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the
standard of care for advanced biliary cancers. We investigated the addition of cetuximab to …

Cholangiocarcinomas are rare biliary tract tumors that are often challenging to diagnose and
treat. Cholangiocarcinomas are generally categorized as intrahepatic or extrahepatic …

Background Combination chemotherapy with gemcitabine and a platinum-based agent is
regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of …

Gallbladder cancer (GBC) is a relatively rare occurrence with a poor prognosis (overall 5-
year survival is 50% for stage I cancers and 3% for stage IV cancers 1). Surgical resection is …